SAN DIEGO—Treatment responses after holmium laser enucleation of the prostate (HoLEP) for symptomatic benign prostatic hyperplasia (BPH) are durable out to 10 years, according patient survey findings presented at the American Urological Association’s 2016 annual meeting.
Tim Large, MD, and colleagues at Indiana University School of Medicine in Indianapolis sent survey questionnaires to 393 eligible HoLEP patients, of whom 115 (29.3%) responded. The mean patient age was 66.3 years at baseline and 77.7 years 10-years post-HoLEP.
Results showed that patients reported a mean decrease in American Urological Association Symptom Score from 21.9 at baseline to 5.1 at 10 years post-HoLEP. The BPH Symptom Index was 1.15 at 10 years compared with 7.4 at baseline.
At 10 years, 72 patients (64.3%) indicated that they were “very satisfied” with the HoLEP procedure and 34 (30.3%) were “satisfied.” In addition, at 10 years post-HoLEP, only 4.3% of patients reported being on alpha-blocker therapy and 3.5% required ancillary procedures. The mean PSA level at 10 years was 1.57 ng/mL versus 7.33 at ng/mL at baseline.
The researchers concluded that the sustained improvements are likely the result of complete removal of the transition zone as evidenced by low PSA levels 10 years after treatment.